For 4QFY2017, Aurobindo Pharma (APL) posted numbers which were lower than expectations on sales, OPM & net profit fronts. On sales front, the company posted sales of `3,582cr (v/s. `4,460cr expected) v/s. `3,674cr in 4QFY2016, posting a yoy de-growth of 2.5%. On the operating front, the EBITDA margin came in at 18.5% (v/s. 23.4% expec..